Jobs / United States / Astrazeneca Pharmaceuticals Lp
Global Clinical Program Lead, Hematology
Astrazeneca Pharmaceuticals Lp · 🇺🇸 US - South San Francisco - CA
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles1 certified filing for “Global Product Teams Finance Director, R&D Finance” (Financial Managers) in MD: $196k–$196k, median $196k. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Astrazeneca Pharmaceuticals Lp
The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Astrazeneca Pharmaceuticals Lp →
About the role
Role: Global Clinical Program Lead, Hematology Hybrid Working: Minimum of 3 days per week in the office Location: This role is advertised in San Francisco, United States . However, applications may also be considered from candidates based in the following AstraZeneca Hematology locations: Boston, Massachusetts; South San Francisco, California; Gaithersburg, Maryland; or Barcelona, Spain . AstraZeneca is a global, science-led, patient-focused biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines for some of the world’s most serious diseases. We are more than one of the world’s leading pharmaceutical companies. AstraZeneca has a multifaceted environment that cultivates collaboration and innovation. We attract top minds, and we nurture and build talent. Within Hematology R&D, we are committed to advancing the science to deliver life-changing medicines to patients most in need. With a combination-focused pipeline that exploits the power of six scientific platforms (Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response, Antibody-drug Conjugates, Cell Therapy and Epigenetics) to help address unmet clinical needs in a host of hematological cancers, we are motivated by a dedication to the scientific discovery and collaboration that will one day help eliminate cancer as a cause of death. This unit has responsibility for the value chain from discovery through to late-stage development, enabling rapid acceleration of promising early-stage assets and life-cycle management programs. The Hematology Research and Early Development (R&D) team has the accountability for all drug development activities in hematology research from first in man studies, all the way to late-stage trials leading to drug approval by regulatory agencies (Phase 1, 2 and 3 trials). The team strives to deliver compelling preclinical, clinical and translational data packages providing confidence in the dosing strategy, tolerability profile and therapeutic efficacy of our candidate drugs to support investment in late stage clinical development, leading to drug approval. We are looking for a highly qualified Global Clinical Program Lead (GCPL) candidate to lead the clinical development and execution of the product strategy for multiple projects. This individual will be accountable for the strategic clinical development plan and clinical execution of the compounds and reports to the Global Clinical Head (GCH) of the disease indication. The individual will articulate the project goals, strategy and the underlying science and clinical need to internal and external audiences with clarity and credibility. In this role the candidate will work with other project leaders, scientific and clinical leaders as well as external experts to coordinated integrated project plans which can be delivered across functional boundaries. The candidate will ensure that diverse views within the team are heard and that a strongly empowered and motivated team is created, and will demonstrate highly visible leadership within the oncology community, both within AZ and externally. The successful candidate will have hematology/oncology clinical drug development experience, demonstrated leadership, and be able to critically navigate the science that underlies these programs. The candidate should be able to effectively communicate across a broad range of audiences and have an ability to clearly articulate project specific strategies as well as the overall oncology strategy. • Leads clinical development teams responsible for novel Hematology Oncology therapies from preclinical candidate selection through proof of concept leading to Phase 3 investment decisions. The candidate will lead all regulatory submissions. Accountable for t